Oxford-ZEISS advances breakthrough live-cell imaging platform for next-gen drug discovery

The 12-month alpha-testing phase will bring together ZEISS R&D, three academic collaborators, and three pharmaceutical industry partners

Symeres and Ambagon team up to target ‘undruggable’ proteins in colorectal cancer

Under the collaboration, Symeres will test Ambagon’s newly designed molecular glues using in vitro assays and mechanistic studies

MedGenome’s RNA-based NGS study sharpens sarcoma diagnosis, alters treatment in 25% cases

India’s first prospective study finds molecular testing improved diagnostic clarity in 50% of complex sarcoma cases

Kauvery Hospital sets new benchmark in high-risk cardiac care

71-year-old high-risk patient with atrial fibrillation and ventricular tachycardia discharged next day

Biotium unveils ViaPlex 2-Color Cell Barcoding Kit to supercharge flow cytometry

The kit features ViaPlex 405 Barcoding Dye for the 405 nm laser/Pacific Blue filter and ViaPlex 488 Barcoding Dye for the 488 nm laser/FITC filter

EU clears AstraZeneca’s Imfinzi combo for early gastric & GEJ cancers

AstraZeneca says the approval strengthens its push to bring immunotherapy earlier into cancer treatment, where long-term cures are possible

Amydis bags $2.5 million NIH grant to develop first eye test for key ALS biomarker

Agilent to acquire Biocare Medical for $950M, supercharging cancer diagnostics portfolio

The acquisition of Biocare enhances Agilent’s pathology portfolio and reflects our strategy to drive long-term growth

Pfizer bags rull FDA nod for BRAFTOVI combination in aggressive colorectal cancer

BRAFTOVI in combination with cetuximab and mFOLFOX6 had previously received accelerated approval in December 2024 based on objective response rate (ORR) results

DNA Nanorobots & AI could slash drug development times, Nanovery CEO says

DNA nanorobots—tiny, self-assembling machines capable of detecting diseases in blood samples within 2–4 hours